AbbVie (ABBV) Profit After Tax (2012 - 2026)

AbbVie has disclosed Profit After Tax across 15 years of filings, most recently posting $697.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 45.93% year-over-year to $697.0 million; the TTM figure through Mar 2026 stood at $3.6 billion (down 13.43% YoY), while the FY2025 annual figure was $4.2 billion, down 1.4% from the prior year.
• Profit After Tax declined to $697.0 million in Q1 2026, from $1.8 billion in the prior quarter.
• Over the last five years, Profit After Tax for ABBV reached as high as $4.5 billion in Q1 2022 and fell as low as -$22.0 million in Q4 2024.
• The 5-year median for Profit After Tax is $1.4 billion (2024), against an average of $1.5 billion.
• Annual changes were most pronounced in 2024 — Profit After Tax tumbled 102.68% — and 2025, when it soared 8354.55%.
• A 5-year view of Profit After Tax shows it stood at $2.5 billion in 2022, then slumped by 66.76% to $822.0 million in 2023, then sank by 102.68% to -$22.0 million in 2024, then soared by 8354.55% to $1.8 billion in 2025, then tumbled by 61.62% to $697.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $697.0 million, $1.8 billion, and $186.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.